Before being treated with nivolumab, 18fluorine-labeled anti-PD-L1 Adnectin (18F-BMS-986192) and 89zirconium-labeled nivolumab (89Zr-nivolumab) were tested in patients with non-small-cell lung cancer (NSCLC). This evidence concerns the gene CD274 and non-small cell lung carcinoma.